| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from CDXS graph: y-stage competitors who are pursuing fully enzymatic approaches to the manufacture of RNA, including EnPlusOne Bioscie… |
| AZN |
AstraZeneca PLC |
72%
|
y-stage competitors who are pursuing fully enzymatic approaches to the manufacture of RNA, including EnPlusOne Biosciences, a private startup company, and a UK-based consortium led by CPI and consist… |
| MANU |
Manchester |
72%
|
y-stage competitors who are pursuing fully enzymatic approaches to the manufacture of RNA, including EnPlusOne Biosciences, a private startup company, and a UK-based consortium led by CPI and consist… |
| MANU |
Manchester |
72%
|
Reciprocal relationship from MANU graph: Reciprocal relationship from CDXS graph: Reciprocal relationship from MANU graph: Reciprocal relationship from CDXS graph: Reciprocal relationship from MANU g… |
| AI-TECHNOLOGIES |
AI-TECHNOLOGIES |
62%
|
rpreting existing laws, could be significant and would increase our operating expenses (such as by imposing additional reporting obligations regarding our use of AI Technologies). Such an increase in… |
| ALDEVRON-LLC-ROCHE-SEQUENCING-SOLUTIONS-INC |
ALDEVRON-LLC-ROCHE-SEQUENCING-SOLUTIONS-INC |
62%
|
rtunities that may be more profitable or for which there is a greater likelihood of success. • We may receive limited revenue or no future value from certain of our existing license agreements. • The… |
| ALMAC-GROUP-LTD |
ALMAC-GROUP-LTD |
62%
|
ming obsolete. Our primary competitors in the performance enzymes for the pharmaceutical products markets include (i) companies marketing either conventional, non-enzymatic processes or biocatalytic … |
| BIOMATTER-DESIGNS-ARZEDA-CORP |
BIOMATTER-DESIGNS-ARZEDA-CORP |
62%
|
y-stage competitors who are pursuing fully enzymatic approaches to the manufacture of RNA, including EnPlusOne Biosciences, a private startup company, and a UK-based consortium led by CPI and consist… |
| BMY |
Bristol-Myers Squibb Company |
62%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from CDXS graph: Reciprocal relationship from BMY graph: Reciprocal relationship from CDXS graph: ming obsolete. Our primary competitor… |
| BRAIN-BIOTECH-AG-ARZEDA-CORP |
BRAIN-BIOTECH-AG-ARZEDA-CORP |
62%
|
ming obsolete. Our primary competitors in the performance enzymes for the pharmaceutical products markets include (i) companies marketing either conventional, non-enzymatic processes or biocatalytic … |
| BRISTOL-MYERS-SQUIBB-KYORIN-PHARMACEUTICAL-CORPO |
BRISTOL-MYERS-SQUIBB-KYORIN-PHARMACEUTICAL-CORPO |
62%
|
ming obsolete. Our primary competitors in the performance enzymes for the pharmaceutical products markets include (i) companies marketing either conventional, non-enzymatic processes or biocatalytic … |
| DSM-FIRMENICH-AG-CAMBREX-CORPORATION-LONZA-GROUP |
DSM-FIRMENICH-AG-CAMBREX-CORPORATION-LONZA-GROUP |
62%
|
ming obsolete. Our primary competitors in the performance enzymes for the pharmaceutical products markets include (i) companies marketing either conventional, non-enzymatic processes or biocatalytic … |
| ENZYMICALS-AG |
ENZYMICALS-AG |
62%
|
y-stage competitors who are pursuing fully enzymatic approaches to the manufacture of RNA, including EnPlusOne Biosciences, a private startup company, and a UK-based consortium led by CPI and consist… |
| GINKGO-BIOWORKS-BRAIN-BIOTECH-AG |
GINKGO-BIOWORKS-BRAIN-BIOTECH-AG |
62%
|
y-stage competitors who are pursuing fully enzymatic approaches to the manufacture of RNA, including EnPlusOne Biosciences, a private startup company, and a UK-based consortium led by CPI and consist… |
| INNOVATUS-CAPITAL-PARTNERS-LLC |
INNOVATUS-CAPITAL-PARTNERS-LLC |
62%
|
roduct gross margin from our unaudited condensed consolidated statements of operations for the periods presented (in thousands, except percentages): Three Months Ended March 31, Change 2026 2025 $ % … |
| MERCK-GSK-NOVARTIS-PFIZER-INC |
MERCK-GSK-NOVARTIS-PFIZER-INC |
62%
|
ming obsolete. Our primary competitors in the performance enzymes for the pharmaceutical products markets include (i) companies marketing either conventional, non-enzymatic processes or biocatalytic … |
| MRK |
Merck & Co., Inc. |
62%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from CDXS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CDXS graph: Reciprocal relationship from MRK grap… |
| NOVARTIS-PHARMA-AG |
NOVARTIS-PHARMA-AG |
62%
|
rtunities that may be more profitable or for which there is a greater likelihood of success. • We may receive limited revenue or no future value from certain of our existing license agreements. • The… |
| NVS |
Novartis AG |
62%
|
Reciprocal relationship from NVS graph: Reciprocal relationship from CDXS graph: rtunities that may be more profitable or for which there is a greater likelihood of success. • We may receive limited … |
| ROCHE-SEQUENCING-SOLUTIONS-INC |
ROCHE-SEQUENCING-SOLUTIONS-INC |
62%
|
Roche Sequencing Solutions, Inc., Crosswalk Therapeutics and Alphazyme LLC, provide for milestone payments, usage payments, and/or future royalty or other payments, which we will only receive if we a… |
| TAKASAGO-INTERNATIONAL-CORPORATION |
TAKASAGO-INTERNATIONAL-CORPORATION |
62%
|
ming obsolete. Our primary competitors in the performance enzymes for the pharmaceutical products markets include (i) companies marketing either conventional, non-enzymatic processes or biocatalytic … |
